Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Cytokine production inhibitors for inflammatory disorders in development at Ortho-McNeil

Dec. 30, 1998

Synvisc cleared for marketing in several Pacific Rim countries

Dec. 29, 1998

Phase II trial results for Immune Response's therapeutic RA vaccine published

Dec. 29, 1998

Combination of PGE1 + rolipram or pentoxifylline shows potential for RA

Dec. 28, 1998

Humanized anti-IL-6 antibody shows good efficacy and safety as rheumatoid arthritis Rx

Dec. 28, 1998

Oral human immunoglobulin proves to be safe and effective treatment for RA

Dec. 23, 1998

Design of potent MAP kinase p38 inhibitors reported by R.W. Johnson

Dec. 23, 1998

Patent assigned to Sumitomo describes new compounds for immune and inflammatory disorders

Dec. 23, 1998

Immune Response announces phase IIb trial results for RA

Dec. 23, 1998

New cell adhesion inhibitors in development at Lilly for inflammatory disorders, etc.

Dec. 22, 1998

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.